Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch

Key Facts

• , /PRNewswire/ -- The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030" is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $113.52 million in 2023 to reach $156.14 million by 2030, at a CAGR of 4.65% over the forecast period.
• "Advancements and Global Initiatives Propel Progressive Familial Intrahepatic Cholestasis (PFIC) Treatment Landscape" Progressive Familial Intrahepatic Cholestasis (PFIC), a group of rare liver disorders caused by genetic anomalies, disrupts bile flow, leading to severe liver conditions.
• Request Analyst Support @ https://www.360iresearch.com/library/intelligence/progressive-familial-intrahepatic-cholestasis-treatment "Ipsen Pharma at the Forefront of Progressive Familial Intrahepatic Cholestasis Treatment Market with a Strong 15.94% Market Share" The key players in the Progressive Familial Intrahepatic Cholestasis Treatment Market include Takeda Pharmaceutical Company Limited, Ipsen Pharma, Mirum Pharmaceuticals, Inc., Sanofi S.A., AbbVie, Inc., and others.
• Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/progressive-familial-intrahepatic-cholestasis-treatment "Dive into the Progressive Familial Intrahepatic Cholestasis Treatment Market Landscape: Explore 188 Pages of Insights, 286 Tables, and 22 Figures" 1.

Click To Read Full Article